Improved long-term performance of pulsatile extracorporeal left ventricular assist device

Abstract

The long-term survival of patients even on "first-generation" extracorporeal LVAD has improved significantly in the recent era. Careful management of cerebrovascular accidents and systemic infection will play important roles in the long-term LVAD management.

Cost‐effectiveness of left ventricular assist devices for patients with end‐stage heart failure: analysis of the French hospital discharge database

“…Improved survival to reflect improved LVAD performance, as recent studies showed that long‐term performance of LVAD had improved in the recent era 22, 23…”

Risk Factor Analysis and Management of Cerebrovascular Accidents in Japanese Patients Supported by Left Ventricular Assist Device

“…The blood contacting surface is covered by segmented polyurethane approved for medical use. (b) Representative pictures of the blood pump with mobile thrombi (upper panel) and a granulating wound at the penetration sites of the inflow/ outflow cannula in the abdominal skin Insurance System as of November 2010 (Sasaoka T et al, 2010). Some implantable LVAD were used for Japanese patients for the purpose of clinical trail, or when medical expense was paid individually.…”

“…Needless to say, some of them died while on the device. Given these circumstances, our long-term management skills for overcoming LVAD-related complications have improved over time, with the 1-year survival now being 82% (Sasaoka T et al, 2010). However, even with this success rate of survival, CVA still remains the leading cause of death.…”

“…Especially in Japan, domestic legal issues had severely limited the number of heart transplantation until the Revised Organ Transplant Law was launched in 2010. The mean waiting period of Japanese heart transplant candidates after left ventricular assist device (LVAD) surgery had exceeded 2 years and occasionally reached 4 years until recently (Sasaoka T et al, 2010). The long-term LVAD support can result in serious complications such as cerebrovascular accident (CVA), the most common cause of death following LVAD surgery (Rose EA et al, 2001;Holman WL, 2009;Saito S, et al 2010).…”

Long-Term Management of Pulsatile Extracorporeal Left Ventricular Assist Device

“…Accordingly, the NCVC has most experience in Toyobo-LVAS® surgeries and has been mostly familiar with this devise management in Japan. Thus, as a representative data of clinical outcome after Toyobo-LVAS® surgery, we introduced the papers regarding Toyobo-LVAS®, which were recently published by our NCVC group Sasaoka T et al, 2010). In order to describe how the survival after Toyobo-LVAS® improved over the years, the retrospectively review of 69 consecutive patients with Toyobo-VAS® as a bridge to heart transplantation between 1994 and 2007 at NCVC were shown.…”